Advanced search
Publication Cover
British Journal of Neurosurgery Volume 13, 1999 - Issue 2
Submit an article Journal homepage
40
Views
18
CrossRef citations to date
0
Altmetric
Research Article

Platinum distribution in malignant glioma following intraoperative intravenous infusion of carboplatin

I. R. WHITTLE Department of Clinical Neurosciences, ICRF Medical Oncology Unit (Department of Clinical Oncology), and the Pharmacy Department, University of Edinburgh, UK
,
G. MALCOLM Department of Clinical Neurosciences, ICRF Medical Oncology Unit (Department of Clinical Oncology), and the Pharmacy Department, University of Edinburgh, UK
,
D. I. JODRELL Department of Clinical Neurosciences, ICRF Medical Oncology Unit (Department of Clinical Oncology), and the Pharmacy Department, University of Edinburgh, UK
&
M. REID Department of Clinical Neurosciences, ICRF Medical Oncology Unit (Department of Clinical Oncology), and the Pharmacy Department, University of Edinburgh, UK
Pages 132-137 | Published online: 06 Jul 2009

  • Dodion P, Sanders C, Georges P, Kenis Y. In vitro chemosensitivity of brain tumours to cisplatin, and its analogues, iproplatin and carboplatin. Cancer Chemother Pharmacol 1988;22:80-2.
  • Doz F, Berens ME, Dougherty DV, et al. Comparison of the cytotoxic activities of cisplatin and carboplatin agaisnt glioma cell lines at pharmacologically relevant drug exposures. J Neurooncol 1991;11:27-35.
  • Lunardi P, Osman Farah J, Mastronardie L, et al. Intravenous administration of high doses of Carboplatin in multimodal treatment of high grade gliomas: a Phase 2 study. Acta Neurochir (Wien) 1996;138:215-20.
  • Poisson M, Pereon Y, Chiras J, et al. Treatment of recurrent malignant supratentorial glioma with Carboplatin (CBDCA). J Neurooncol 1991;10:139-44.
  • Twelves CJ, Ash CM, Miles CW, et al. Activity and toxicity of carboplatin and iproplatin in relapsed high grade glioma. Cancer Chemother Pharmacol 1991;27:481-3.
  • Warnick RE, Prados MD, Mack EE, et al. A phase 2 study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol 1994;19:69-74.
  • YungWK, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma. A phase 2 study. J Clin Oncol 1991;9:860-4.
  • Cloughesy T, Black KL. Pharmacological blood-brain barrier modification for selective drug delivery. J Neurooncol 1995;26:125-32.
  • Koga H, Inamura T, Ikezaki K, et al. Increased delivery of a new cisplatin analogue (254-S) in rat brain tumour by an intracarotid infusion of bradykinin. Neurol Res 1996;18:244-7.
  • Matsukado K, Inamura T, Nakano S, et al. Enhanced tumor uptake of Carboplatin and survival in gliomabearing rats by intracarotid infusion of bradykinin analog RMP-7. Neurosurgery 1996;39:125-34.
  • Nomura T, Inamura T, Black KL. Intracarotid infusion of bradykinin selectively increases blodd-tumour permeability in 9L and C6 brain tumours. Brain Res 1994;659:62-6.
  • Gregor A, Lind M, Osborn C, et al. RMP-7 and carboplatin in recurrent malignant glioma. J Neurooncol 1997;35(Suppl 1):S54.
  • Calvert AH, Newell DR, Grumbell LA, et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
  • Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
  • van der Vijh WJF. Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 1991;21:242-61.
  • Unterberg A, Dautermann C, Baethmann A, et al. The kallikrein-kinin system as a mediator of vasogenic brain edema; part 3 inhibition of the kallikrein-kinin system in traumatic brain swelling. J Neurosurg 1986;64:269-76.
  • Matsukado K, Nakano S, Bartus R, et al. Steroids decrease uptake of carboplatin in rat gliomas- uptake improved by intracarotid infusion of bradykinin analog, RMP-7. J Neurooncol 1997;34:131-8.
  • Malcolm GP, Jodrell D, MacLennan A, Kelly PAT, Swaroop GR, Whittle IR. The effects of nitric oxide modulation on carboplatin disposition in experimental glioma. Neuroreport 1998;9:181-5.
  • Malcolm GP, Kelly PAT, Whittle IR. The effects of NO-nitro-L-arginine methyl ester and 3-morpholinosydnonimine upon local cerebral blood flow in an implantation glioma model in rat. Br J Pharmacol 1995;116:274.
  • Whittle IR, Collins F, Kelly PA, et al. Nitric oxide synthase is expressed in experimental malignant glioma and influences tumour blood flow. Acta Neurochir (Wien) 1996;138:870-6.
  • Shinohara C, Matsumoto K, Kuriyama M, et al. Clinical pharmacokinetics of carboplatin and MCNU in malignant brain tumours and normal brain tissues. J Cancer Chemother 1994;21:1163-8.
  • Donelli MG, Zuchetti M, D'Incalci M. Do anticancer agents reach the tumour target in the human brain. Cancer Chemother Pharmacol 1992;30:251-60.
  • Black KL, Cloughesy T, Huang SC, et al. Intracarotid infusion of RMP-7, a bradykinin analogue and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J Neurosurg 1997;86:603-9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.